Study Projects 83% Rise in Childhood Hepatitis B Under CDC's Shared-Decision Policy

A modeling study published this week in Annals of Internal Medicine projects that the federal government's shift away from universal hepatitis B vaccination at birth will substantially increase the number of American children who develop chronic hepatitis B infections, with consequences that trail those children into adulthood.

The study, led by researchers at Massachusetts General Hospital and Harvard Medical School, built a Markov state-transition model around a single-year U.S. birth cohort of 3.6 million infants. It compared three scenarios: universal vaccination at birth, a deferred strategy starting at two months, and the approach now in place, which leaves the timing to shared decision-making between parents and clinicians.

The results are worth reading carefully. The universal birth-dose strategy produces an estimated 255 chronic hepatitis B infections over 20 years in that cohort. Deferring to two months raises that number to 303, a 19% increase. But the shared decision-making approach, according to the model published in Annals, is projected to produce 467 chronic infections, an 83% increase over universal vaccination at birth.

The population that carries the real weight of this projection is infants whose mothers were never identified as hepatitis B positive, either because prenatal testing was missed or because the mother was seronegative but exposure happened anyway. The study used published data that put maternal HBV prevalence at 0.4% and assumed that roughly 27% of pregnancies don't receive adequate prenatal HBsAg testing.

What makes those chronic infection numbers clinically significant is what happens downstream. As reported by Healthline in its coverage of the study, up to 90% of infants infected with hepatitis B in their first year develop chronic infection, which can progress to cirrhosis, liver failure, or liver cancer. That's not a distant or theoretical risk. It's the reason the birth-dose policy existed in the first place.

The CDC ended its universal birth-dose recommendation in late 2025, under HHS Secretary Robert F. Kennedy Jr., shifting to individualized clinical decision-making for infants born to mothers who test negative for the virus. The Advisory Committee on Immunization Practices voted 8 to 3 for the change, following what STAT News described as more than a day of contentious discussion. The American Academy of Pediatrics has not moved with the CDC and still recommends universal vaccination within 24 hours of birth.

The model also projected long-term susceptibility. Under shared decision-making, more than 1.8 million members of a single birth cohort would remain susceptible to hepatitis B infection by the time they reach adulthood 20 years later, compared with 232,000 under universal vaccination at birth, according to findings published in Annals of Internal Medicine.

A dissenting read from immunologist James Lyons-Weiler, posted on Substack on October 24, argues that the 83% figure combines delayed timing with an assumed drop in overall vaccine series completion, and that the timing effect alone isn't established by immunological data. That's a fair methodological flag. The authors used a published vaccine-completion rate of 50% under shared decision-making, which is an assumption, not an observed outcome of the current policy.

Still, that assumption reflects a documented pattern in pediatric practice: when a vaccine is no longer recommended at birth, first-contact administration drops, and series completion tends to follow it down. Nurses and pediatricians who've managed vaccine schedules in primary care know that the birth hospitalization is often the most reliable administration point a child will ever have.

The CDC has not responded publicly to the study's conclusions. What it said when it changed the recommendation last year was that newborns of hepatitis B-negative mothers face little immediate risk. The Annals model tests what that reasoning costs over a generation.

Sources cited:
- Annals of Internal Medicine (https://www.acpjournals.org/doi/10.7326/ANNALS-26-02135)
- Healthline (https://www.healthline.com/health-news/rfk-jr-vaccine-schedule-changes-may-cause-surge-hepatitis-b)
- CIDRAP (University of Minnesota) (https://www.cidrap.umn.edu/hepatitis/study-findings-support-hepatitis-b-vaccine-birth-dose-over-other-strategies)
- STAT News (https://www.statnews.com/2025/12/05/cdc-hepatitis-b-vaccination-acip-panel-overturns-30-year-policy/)
- Medical Xpress (https://medicalxpress.com/news/2026-10-hepatitis-vaccination-significantly-infections.html)
- Popular Rationalism (Substack) (https://popularrationalism.substack.com/p/new-hepatitis-b-vaccine-study-suggests)